New method of microwave thermokeratoplasty to correct myopia in 33 eyes: One-year results
Journal of Cataract and Refractive Surgery, cilt.39, sa.2, ss.225-233, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 39 Sayı: 2
- Basım Tarihi: 2013
- Doi Numarası: 10.1016/j.jcrs.2012.08.066
- Dergi Adı: Journal of Cataract and Refractive Surgery
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.225-233
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To assess the safety, predictability, and stability of a new microwave thermokeratoplasty procedure to correct myopia. Setting: Cornea and refractive surgery subspecialty. Design: Prospective clinical trial. Method: Thermokeratoplasty was performed in myopic eyes at a single center in Turkey from June 2009 to June 2010. The attempted corrections ranged from -1.25 to -5.75 diopters (D). The main outcome measures were changes in logMAR uncorrected distance visual acuity (UDVA) and in keratometry (K) values. Results: The procedure was performed in 33 eyes (patients aged 20 to 45 years). The mean preoperative logMAR UDVA (0.76 ± 0.24 [SD]) significantly improved to 0.19 ± 0.20 at 1 month, postoperatively. By 3 months, the mean UDVA had markedly regressed to 0.59 ± 0.29; however, the residual improvement remained statistically significant. At 12 months, the mean logMAR UDVA was 0.72 ± 0.26. The mean K values were 43.9 ± 1.36 D preoperatively, 41.25 ± 2.63 D at 1 month, 43.4 ± 1.69 D at 3 months, and 44.1 ± 1.09 D at 12 months. The mean endothelial cell density was 2836 ± 342 cells/mm2 preoperatively and were statistically unchanged 12 months postoperatively (2732 ± 353 cell/mm2). No patient lost lines of corrected distance visual acuity by 12 months postoperatively. Conclusions: The new thermokeratoplasty procedure produced the desired reduction in myopia and improvement in postoperative UDVA 1 month postoperatively without significant side effects. However, early and complete regression shows the need for further development of this technique. Financial Disclosure: Drs. Yilmaz and Marshall are paid consultants to Avedro, Inc., and Dr. Muller is president and CEO of Avedro, Inc. No other author has a financial or proprietary interest in any material or method mentioned. © 2012 ASCRS and ESCRS.